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Abstract
Background: Complete and transparent reporting of clinical trial protocols and reports ensures that these documents
are useful to all stakeholders, that bias is minimized, and that the research is not wasted. However, current studies
repeatedly conclude that pediatric trial protocols and reports are not appropriately reported. Guidelines like SPIRIT
(Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT (Consolidated Standards of
Reporting Trials) may improve reporting, but do not offer guidance on issues unique to pediatric trials. This paper
reports two systematic reviews conducted to build the evidence base for the development of pediatric reporting
guideline extensions: 1) SPIRIT-Children (SPIRIT-C) for pediatric trial protocols, and 2) CONSORT-Children (CONSORT-C)
for pediatric trial reports.
Method: MEDLINE, the Cochrane Methodology Register, and reference lists of included studies were searched.
Publications of any type were eligible if they included explicit recommendations or empirical evidence for the
reporting of potential items in a pediatric protocol (SPIRIT-C systematic review) or trial report (CONSORT-C
systematic review). Study characteristics, recommendations and evidence for pediatric extension items were
extracted. Recurrent themes in the recommendations and evidence were identified and synthesized. All steps
were conducted by two reviewers.
Results: For the SPIRIT-C and CONSORT-C systematic reviews 366 and 429 publications were included, respectively.
Recommendations were identified for 48 of 50 original reporting items and sub-items from SPIRIT, 15 of 20 potential
SPIRIT-C reporting items, all 37 original CONSORT items and sub-items, and 16 of 22 potential CONSORT-C reporting
items. The following overarching themes of evidence to support or refute the utility of reporting items were identified:
transparency; reproducibility; interpretability; usefulness; internal validity; external validity; reporting bias; publication
bias; accountability; scientific soundness; and research ethics.
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Conclusion: These systematic reviews are the first to systematically gather evidence and recommendations for the
reporting of specific items in pediatric protocols and trials. They provide useful and translatable evidence on which to
build pediatric extensions to the SPIRIT and CONSORT reporting guidelines. The resulting SPIRIT-C and CONSORT-C will
provide guidance to the authors of pediatric protocols and reports, respectively, helping to alleviate concerns of
inappropriate and inconsistent reporting, and reduce research waste.
Keywords: Clinical trials, Protocols, Systematic review, Reporting, SPIRIT, SPIRIT-C, CONSORT, CONSORT-C
Background
High-quality clinical trials provide the best evidence for
efficacy and safety of interventions [1], and are required
to improve upon our current paucity of evidence in
children [1, 2]. However, researchers have an ethical ob-
ligation to only include children in trials that are appro-
priately conducted and reported [1–4]. Complete and
transparent reporting of trial protocols and reports en-
sures that these documents are useful to all stakeholders
[3, 4], that bias is minimized [4–7], and that the research
is not wasted [3, 4]. It also allows the readers of trial
protocols and reports to critically assess trial method-
ology, ethical considerations, and internal and external
validity [8].
Systematic reviews of pediatric literature have repeat-
edly concluded that pediatric trial reports are not appro-
priately reported [3, 4, 6, 9–17]. Despite reporting
guidelines for trial reports, reviewers identified gaps in
reporting across pediatric specialties, including inad-
equate reporting of important items such as adverse
events [4, 12, 13, 18], interventions [12–14, 19], out-
comes [12, 20], sequence generation [12, 20], allocation
concealment [12, 20], blinding [11, 12], sample size cal-
culations [11, 12], consent and assent information [21],
and many more [12, 20, 22].
Similarly, Tetzlaff et al. [23] and others [24–26] have
described inappropriate reporting in trial protocols. Des-
pite protocol-reporting guidelines, reviewers identified
gaps in reporting of outcomes [24], allocation conceal-
ment [25], sample size calculations [26], and sponsor
and investigator roles [27].
The SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials) [28] and CONSORT
(Consolidated Standards of Reporting Trials) [8] initia-
tives aim to harmonize and standardize reporting guide-
lines to tackle the problem of inappropriate reporting in
trial protocols and reports, respectively. Reporting guide-
lines provide checklists of specific concepts, called
reporting items, which need to be addressed in docu-
ments such as protocols and trial reports. SPIRIT is a
protocol-reporting guideline that identifies 33 key
reporting items and 17 sub-items to be addressed in all
clinical trial protocols. CONSORT is a reporting
guideline that identifies 25 key reporting items and 12
sub-items to be addressed in all clinical trial reports upon
completion of the clinical trial. The guidelines, when
followed, allow the readers of trial protocols and reports
to critically assess trial methodology, ethical consider-
ations, as well as internal and external validity. Although
these guidelines may improve reporting [4], neither
SPIRIT nor CONSORT offer guidance on issues unique
to pediatric trials [1–3, 6, 13, 14, 29].
Scientific, ethical and safety considerations for trials
with children often differ from trials with adults [2]. As
it is unethical to expose children to the risks of research
unless it is scientifically valid, and inadequate reporting
of pediatric-specific considerations may lead to biased
estimates of treatment effects [6], these considerations
must be accounted for in the trial protocol and report
[1, 5, 14, 21, 22, 29]. For example, growth and matur-
ation must be considered in all aspects of pediatric trial
design and interpretation [1, 3, 29] as it alters pharmaco-
kinetics, metabolism, excretion, drug efficacy, receptors,
and end-organ drug responses [2, 30–37]. Maturation
and development does not happen in a linear fashion
[31, 34, 38–40]. Consequently, pediatric clinical trial de-
sign requires an in-depth understanding of developmen-
tal trajectory in the eligible population during the trial
period [31, 34, 38–40]. Failure to account for growth
and maturation when designing a pediatric clinical trial
can lead to inappropriate interventions which could re-
sult in therapeutic failure or serious adverse events in
children [2, 30, 31, 33, 41, 42].
These pediatric-specific scientific, ethical and safety
consideration differences have led to repeated calls for
pediatric-specific reporting guidance [1–3, 6, 13, 14].
Empirically developed pediatric extensions of the SPIRIT
and CONSORT guidelines are needed to ensure these
issues are appropriately reported in pediatric trial proto-
cols and reports. Failure to account for these differences
in trial protocols can lead to biased or inappropriate tri-
als [4–7], or protocols that are too ambiguous to be use-
ful to all stakeholders [3, 4]. Failure to account for these
differences in trial reports can lead to biased reporting
[4–7], research that is not useful to all stakeholders [3, 4],
and is, therefore, considered waste of research [3].
Pediatric extensions of the SPIRIT and CONSORT
guidelines will help ensure that readers can critically
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assess pediatric-specific issues relating to trial method-
ology, ethical considerations, trial conduct, and internal
and external validity of trial results [8]. In this paper
we report two systematic reviews conducted to build
the evidence base for the prospective development of
pediatric reporting guideline extensions: SPIRIT-
Children (SPIRIT-C) for pediatric trial protocols and
CONSORT-Children (CONSORT-C) for pediatric trial
reports. The systematic reviews to build evidence for the
planned SPIRIT-C and CONSORT-C extensions will be
referred to as the “SPIRIT-C systematic review” and the
“CONSORT-C systematic review,” respectively. Potential
reporting items to be included in each extension were
identified through environmental scans of existing item
recommendations [1] and Delphi studies.
Objectives
The objectives of this SPIRIT-C systematic review are to:
(1) identify empirical evidence to support or refute the
importance of reporting original SPIRIT and candidate
SPIRIT-C extension items, in terms of pediatric trial de-
sign, conduct, or interpretation, (2) identify recommen-
dations for the reporting of specific SPIRIT and SPIRIT-C
protocol items, and (3) identify any additional methodo-
logical and ethical issues that are specific to pediatric
trials.
The objectives of this CONSORT-C systematic review
are to: (1) identify empirical evidence to support or re-
fute the importance of reporting original CONSORT
and candidate CONSORT-C trial extension items, in
terms of pediatric trial design, conduct, or interpret-
ation, (2) identify recommendations for the reporting
of specific CONSORT and CONSORT-C trial report
items, and (3) identify any additional methodological
and ethical issues that are specific to pediatric trials.
Identification of candidate extension items
Prior to this systematic review, candidate extension
items were identified in accordance with best practices
for reporting guideline extension development [43]: (1) a
literature review identified the initial list of potential
pediatric-specific SPIRIT-C and CONSORT-C extension
reporting items; (2) a Delphi exercise contributed input
from diverse stakeholders on the inclusion, exclusion, and
addition of new potential SPIRIT-C and CONSORT-C
extension reporting items.
The results of these systematic reviews will be brought
to a consensus meeting of international pediatric trial
experts and stakeholders to draft pediatric extensions of
the SPIRIT and CONSORT guidelines, and will provide
the evidence base of studies for the development of the
SPIRIT-C and CONSORT-C Statement and Explanation
and Elaboration documents.
Methods
We used the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) reporting guide-
line [44] to prepare this report on our two reviews. All
criteria and search terms were pre-specified, but a for-
mal protocol was not created. An ethics approval was
not required for this work.
Eligibility criteria and definitions
Publications of any type were eligible if they included
explicit recommendations for reporting in a pediatric
trial protocol (for the SPIRIT-C systematic review) or
trial report (for the CONSORT-C systematic review),
and/or if they included empirical evidence to support or
refute reporting concepts in a pediatric trial protocol or
trial report.
An explicit recommendation or endorsement for the
reporting of an item was regarded as a recommendation.
An example of a statement regarded as a recommenda-
tion for the reporting of an item follows, from Smith et
al.: “We argue that parental consenting procedures
should be routinely reported as a methodological feature
of adolescent treatment outcome studies …” [45].
Any information that supported or refuted the import-
ance of a reporting item in pediatric clinical trials was
defined as evidence. Our definition of evidence is con-
sistent with the types of evidence recommended to
support a reporting guideline, which includes both
empirical evidence of effects or biases associated with
inadequate reporting of an item and any other evi-
dence cited to support the reporting of an item [43].
An example of a statement regarded as evidence follows,
also from Smith et al.: “(Reporting of consent procedures
is recommended) … given concerns about sample bias in
adolescent risk behavior research when parental consent
is required, (and) … to prospectively study the impact of
consenting procedures on both the study participation
rates and substance use reporting” [45].
A publication was considered pediatric if it included
pediatric participants as defined by the authors of the
publication. All publication years were eligible. Publica-
tion language was limited to English. Studies and confer-
ence proceedings published only as abstracts were
excluded, as were duplicate or secondary publications.
Information sources
Eligible publications were identified through: a sys-
tematic search of electronic databases, reference lists
of articles, a systematic review of reporting guidelines
by Tetzlaff et al. [23] for the SPIRIT-C systematic re-
view, and the EQUATOR network (Enhancing the
QUality and Transparency Of health Research) data-
base [46]. The systematic searches were conducted in
MEDLINE including in-process and non-indexed citations
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(1946 – Present) and adapted for The Cochrane
Methodology Register (CMR) (1995 – Present), using
the Ovid interface. The last searches were run on 16
May 2014 for CONSORT-C MEDLINE, 7 July 2014
for SPIRIT-C MEDLINE and CMR, and 25 July 2014
for CONSORT-C CMR. The MEDLINE searches are
presented in Additional files 1 and 2. The SPIRIT-C
MEDLINE and CONSORT-C MEDLINE search were
amended for the SPIRIT-C CMR and CONSORT-C
CMR searches, respectively. Duplicates were removed
in EndNote X6 (Thomson Reuters Corporation, New
York, NY, USA).
Study selection: title and abstract screening
For each systematic review, two unblinded reviewers
(ACS and PT) independently screened titles and ab-
stracts for eligibility using the pre-defined eligibility cri-
teria. When titles and abstracts contained insufficient
information to assess whether the paper could contain
recommendations or evidence as defined by the eligibil-
ity criteria, the paper was included for full-text assess-
ment to ensure that recommendations or evidence were
not missed. When the eligibility of an abstract was un-
clear, they were included to be re-evaluated for eligibility
when reviewing full-texts during the data collection
process. The result of this screening approach was that
all studies addressing the pediatric population in their
title or abstract were assessed in full-text as they may
have contained recommendations or evidence. Abstracts
that did not address the pediatric population were
excluded. Disagreements on the interpretation of the
eligibility criteria were resolved by consensus or by the
involvement of a third reviewer (WC).
Data collection process: full-text review
Data extraction forms were developed for each system-
atic review, presented in Additional file 3 for SPIRIT-C
and Additional file 4 for CONSORT-C, and pilot-tested
on at least 10 randomly-selected included studies. Two
unblinded reviewers (ACS and PT) independently ex-
tracted data from all included studies using the data ex-
traction forms. Disagreements on the extracted data
were resolved by consensus or by the involvement of a
third reviewer (WC).
Data items
The following data were extracted from each included
study, if found: study characteristics (first author, year,
title, journal, study type, country, target population, trial
design, and area of study based on the main topic of the
publication itself ); recommendation for reporting of an
item; description of the recommendation (the intended
study design, whether the recommendations were sup-
ported with evidence, and the level of that evidence);
evidence for the reporting of an item; description of the
evidence for the reporting of each item; recommenda-
tions for the reporting of items other than the exist-
ing SPIRIT or CONSORT items and SPIRIT-C or
CONSORT-C candidate items; descriptions of trial
methodology issues that are specific to trials with
children or may deviate from adult trials; how these
trial methodology issues may have been overcome
within the studies; description of ethical issues that
are specific to trials with children; and how these eth-
ical issues may have been overcome. Due to the na-
ture of the review, risks of bias of individual studies
were not formally assessed.
Thematic synthesis of results
For each systematic review, two unblinded reviewers
(ACS and PT) independently analyzed the combined ex-
tracted data from all included studies using thematic
synthesis method for qualitative research [47]. The syn-
thesis was completed in three stages: i) coding of the
evidence; ii) organization of the codes into descriptive
themes; and iii) development of analytical themes [47].
Thematic synthesis was outside the scope of the current
study and not performed on the following data items:
descriptions of trial methodology issues that are specific
to trials with children or may deviate from adult trials,
and how these trial methodology issues may have been
overcome within the studies; description of ethical issues
that are specific to trials with children, and how these
ethical issues may have been overcome.
Coding of the evidence
Evidence and recommendations for the reporting of
each item were identified. The evidence from the lit-
erature for the reporting of each item was coded by
two reviewers inductively by the meaning and content
of the evidence [47]. For example, the following evi-
dence for the reporting of CONSORT-C Item 2a.1:
“Describe the reason to perform the clinical trial in
children,” was extracted from Rothenberger et al.: “A
solid scientific justification is an ethical requirement
for studies including minors. If this justification is not
satisfying, studies may be performed in adults but not
in children. Ninety-one of 175 publications (52 %)
gave a scientific justification for including minors, 84
publications (48 %) did not” [48]. This example of
evidence was coded as “Scientific justification.” After
coding the evidence, reviewers compared their codes,
resolved any differences, and collaboratively created
one final version of coding.
Descriptive and analytic themes
Similar codes were then grouped together by two inde-
pendent reviewers to create descriptive themes in the
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meaning and content of the evidence [47]. The resulting
descriptive themes were compared and differences were
resolved to collaboratively create one final group of de-
scriptive themes. One reviewer (ACS) used the descrip-
tive themes of the evidence to infer answers to the
research question: “Why recommend this pediatric-
specific reporting item?” For example, evidence that was
coded as “Scientific justification” was interpreted by the
reviewer as answering the research question as follow-
ing: “The reporting of this item ensures the inclusion of
children is justified.” By interpreting the descriptive
themes as answers to the research question, we were
able to infer analytical themes. Similar inferred an-
swers to our research question based on the descrip-
tive themes of the evidence were grouped together to
form analytical themes. For example, the inferred an-
swers: “The reporting of this item ensures the inclu-
sion of children is justified” and “The reporting of this
item allows readers to assess whether informed con-
sent and assent procedures were appropriate,” were
grouped to form the analytical theme “Research ethics.”
The resulting analytic themes were reviewed by an-
other reviewer (PT) and disagreements were collab-
oratively resolved to create the final group of analytic
themes. Studies that contained a piece of evidence to
form each analytical theme were summarized to high-
light the types of analytic themes supporting potential
reporting items. Due to the qualitative nature of the
review, publication bias and heterogeneity were not
formally assessed.
Results
A total of 2558 publications were identified through the
SPIRIT-C MEDLINE and CMR database searches
(Fig. 1). After screening titles and abstracts, 534 eligible
full-text publications were identified. Findings from 353
relevant publications, along with 13 reporting guidelines
from Tetzlaff et al. [1], were included in this review.
CONSORT-C MEDLINE and CMR database searches
identified a total of 1783 publications (Fig. 2). After
screening titles and abstracts, 697 eligible full-text publi-
cations were identified. Findings from 407 relevant pub-
lications, along with 22 referenced publications, were
included in this review. General characteristics of the
included publications for SPIRIT-C and CONSORT-C
systematic reviews are shown in Tables 1 and 2.
The largest category of the publications included in
these reviews was commentary or review papers, totaling
54 % of included SPIRIT-C publications and 40 % of
included CONSORT-C publications. The majority of
included publications addressed only the pediatric
population, totaling 74 % of included SPIRIT-C publi-
cations and 70 % of CONSORT-C included publica-
tions. Only a minority of the publications contained
explicit recommendations for reporting, totaling 25 %
of SPIRIT-C included publications and 31 % of
CONSORT-C included publications. Of these publica-
tions that contained explicit recommendations for
reporting, 54 % of SPIRIT-C publications and 71 % of
CONSORT-C publications provided evidence for their
recommendations.
Fig. 1 Flow of publications through the systematic review process
for SPIRIT-C
Fig. 2 Flow of publications through the systematic review process
for CONSORT-C
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Recommendations and evidence
Additional files 5 and 6 summarize quantitative and
qualitative information regarding the presence of recom-
mendations and/or evidence for the reporting of items
in the proposed pediatric protocol and trial report,
respectively. Raw and synthesized datasets for both
systematic reviews are available for download and review
at (http://hdl.handle.net/10864/10880) [49]. Of the 50
original reporting items and sub-items in SPIRIT, 48
were recommended for reporting by publications
reviewed in systematic review; of the 20 potential ex-
tension items in SPIRIT-C, 15 were recommended.
All 37 original reporting items and sub-items in
CONSORT were recommended for reporting by pub-
lications reviewed, and 16 of the 22 potential exten-
sion items for CONSORT-C were recommended. No
recommendation or evidence was identified that refuted
the reporting of any items.
There was an average of 4.6 unique publications
(standard deviation: 4.3; range: 0–17) providing recom-
mendations for the reporting of an item in SPIRIT. An
average of 16.2 unique publications (standard deviation:
17.2; range: 0–63) contributed evidence for reporting a
SPIRIT item. An average of 2.6 unique publications
(standard deviation: 1.9; range: 0–8) provided recom-
mendations for an item in CONSORT. On average, 27.6
publications contributed evidence for an item (standard
deviation: 13.3; range: 0–82) for CONSORT. The ori-
ginal SPIRIT Item 26a on consent or assent was most
prominently supported with 63 publications contributing
evidence and the SPIRIT-C extension Item 26a.1 on the
justification for the use of proxy consent and indication
of who will be eligible to provide it was well-supported
with 63 publications contributing evidence (Additional
file 5). Within the CONSORT-C systematic review, the
original CONSORT Item 2a on scientific background
and explanation of rationale was most prominently
Table 1 General characteristics of the included publications for
the SPIRIT-C (n = 366) and CONSORT-C (n = 429) systematic
reviews
SPIRIT-C n (%) CONSORT-C n (%)
Type of publication
Clinical trial 21 (6) 40 (10)
Systematic review 34 (9) 92 (21)
Meta-analysisa 5 (1) 22 (5)
Commentary/reviewb 197 (54) 173 (40)
Cohort/cross-sectional 70 (19) 52 (12)
Protocol 23 (6) 15 (4)
Other 16 (5) 35 (8)
Target population
Adult only 16 (4) 22 (5)
Pediatric only 271 (74) 299 (70)
All 79 (22) 108 (25)
Date of publication
1971–1980 5 (1) 4 (1)
1981–1990 18 (5) 15 (4)
1991–2000 55 (15) 58 (13)
2001–2010 166 (45) 224 (52)
2011–2014 122 (34) 128 (30)
Presence of any explicit recommendationc to report an item
Yes 92 (25) 133 (31)
No 274 (75) 296 (69)
For these explicit recommendations (n = 92 for SPIRIT, and n = 133 for
CONSORT), evidencec identified
Yes 54 (59) 95 (71)
No 38 (41) 38 (29)
Source of evidence for recommendations identified
Literature review 12 (22) 29 (31)
Systematic review 5 (9) 28 (29)
Clinical trial 2 (4) 3 (3)
Consensus 9 (17) 6 (6)
Expert opinion 26 (48) 27 (29)
N/A 0 (0) 2 (2)
aIncludes meta-analysis and systematic review
bIncludes commentaries, editorials, opinions, and non-systematic
literature reviews
cAs defined in Method
Table 2 Subject foci of included publications for the SPIRIT-C
(n = 366) and CONSORT-C (n = 429) systematic reviews, as
identified by reviewer consensus
SPIRIT-C n (%) CONSORT-C n (%)
Disability 8 (2) Alternative medicine 7 (2)
Ethics 72 (20) Ethics 38 (9)
Evidence-based medicine 17 (5) Evidence-based medicine 19 (3)
Infectious diseases 6 (2) Immunology 16 (4)
Methodology 176 (48) Infectious diseases 11 (3)
Nephrology 3 (1) Mental health 48 (11)
Neurology 9 (2) Methodology 150 (35)
Nutrition 5 (1) Neurology 16 (4)
Obstetrics 2 (1) Nutrition 6 (1)
Oncology 8 (2) Obstetrics 12 (3)
Pharmacology 20 (5) Oncology 18 (4)
Psychiatry 20 (5) Pharmacology 25 (6)
Public health 6 (2) Public health 13 (3)
Respiratory medicine 8 (2) Respiratory medicine 21 (5)
Surgery 6 (2) Surgery 22 (5)
Urology 7 (2)
Publication foci are not mutually exclusive
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supported with 44 publications contributing evidence
and the CONSORT-C extension Item 6a.1 on the valid-
ity of outcomes for the age groups was well-supported
by the evidence with 82 publications contributing evi-
dence (Additional file 6).
Thematic synthesis
The empirical evidence identified for the reporting of
specific items for pediatric trial protocols and trial re-
ports was categorized into descriptive themes (see
Additional file 7) and then into the following analytic
themes: scientific soundness; research ethics; internal
validity; accountability; external validity; transparency;
reproducibility; interpretability; usefulness; reporting
bias; and publication bias (see Table 3). Table 3 provides
illustrative quotations from included studies support-
ing each analytic theme. For both SPIRIT-C and
CONSORT-C, descriptive and analytical themes mir-
rored each other. The first five themes reflect scien-
tific conduct of a clinical trial while the remainder
deal with reporting of a clinical trial.
The systematic reviews outlined in this paper identify
recommendations and evidence that could support or
refute potential reporting items for pediatric protocols
and trial reports. A majority of the potential reporting
items had recommendations and/or evidence identified
in the literature through these reviews. Both reviews
further identified methodological and ethical consider-
ations to be taken into account when conducting and
reporting pediatric trials that distinctly differ from trials
in adults, which we will discuss in detail below.
The recommendations for the reporting of specific items
in pediatric protocols and trial reports
Our systematic reviews identified that a majority of the
potential reporting items had recommendations in the
literature for their reporting. These recommendations
illustrate that many potential reporting items align with
what these authors are already looking for in protocols
and trial reports. They also suggest the need for the
extension of current reporting guidelines for pediatric
trials to include the pediatric-specific reporting items
recommended in the articles we found in our systematic
reviews. Moreover, they indicate a receptive response
among the pediatric research community to the develop-
ment of reporting guidelines that adopt these items.
The empirical evidence for the reporting of specific items
in pediatric protocols and trial reports
Similar to the recommendations, the majority of poten-
tial reporting items had supporting evidence in the
included studies. The over-arching theme was the con-
sideration of pediatric age during the design, conduct
and reporting of pediatric relevant trials. The age(s) of
Table 3 Examples of study text that were categorized in each analytic theme
Analytic theme Example of study text that was categorized within the analytic theme
Transparency “It is our hope that more transparent reporting on consenting procedures, sample composition, and demographic
characteristics would enable future studies on the association between consenting procedures and these variables,
which may ultimately increase our knowledge about the impact of the unspoken rule requiring the collection of
parental consent.” [45]
Reproducibility “Other investigators should be able to replicate a vaccine trial in different settings and populations. Outcomes across
trials can then be compared using: for example, the same serological cutoff points at the same intervals.” [14]
Interpretability “Experienced practitioners and researchers also need to appreciate how setting and child characteristics affect the
validity and interpretation of measures.” [158]
Usefulness “When designing an RCT, investigators must also specify the size of the treatment effect that can be detected
reliably with the proposed sample size. This minimum detectable treatment difference and the actual choice of
the primary outcome strongly affect the clinical utility of the study results.” [159]
Internal validity “Hence, it is the authors’ responsibility to demonstrate the measurement properties (validity, reliability, responsiveness)
of the outcome measures used in their studies.” [160]
External validity “As stated previously, investigators should justify such exclusions. Overly restrictive criteria concerning exclusion of
patients with concurrent diagnoses seriously limit the generalizability of study results.” [161]
Reporting bias “Selective reporting of clinical trials can also hamper the ability of conducting systematic reviews of the pediatric
literature.” [89]
Publication bias “Registration also provides a mechanism for addressing publication bias.” [162]
Accountability “Why register trials? To satisfy public demand for unbiased evidence on the effectiveness of treatments, and to
promote the public accountability of medical research in general.” [163]
Scientific soundness “Environmental research with children should be scientifically justified, with sound research questions and valid
study protocols of sufficient statistical power …” [164]
Research ethics “In our opinion, it is very important for ethical reasons to state at least if informed consent was obtained and if the
study was approved by the responsible REC.” [165]
RCT randomized controlled trial
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the participating children affects all aspects of a trial, in-
cluding choice of intervention and comparator, selection
and measurement of relevant and valid outcomes, ex-
pected treatment effect, differences in risk/benefit pro-
file, effects on growth and development and disease
processes [21, 34, 48, 50–65]. Therefore, the detailed
reporting of the age distribution of children in a trial is
essential for the assessment of the appropriateness of
age groups selected, the interventions, and outcomes,
and the potential effects on growth and development.
Within this context, three analytic themes identified in
support of reporting items are summarized below, pre-
senting some of the more prominent examples:
1. Scientific soundness. One analytic theme for reporting
an item was to allow the reader to assess whether the
pediatric protocol or trial report was scientifically
sound. For example, the reporting of the effectiveness
of an intervention in children, or lack thereof, allows
the reader to critically evaluate whether the trial was
scientifically justified. To justify a trial, authors must
provide the reason to believe this intervention could
be effective in children [66, 67], but that current
information on this possible effectiveness is not
conclusive [67–77]. Addressing known differences
in pharmacokinetics and pharmacodynamics between
children and adults allows the reader to evaluate
whether the trial was justified and appropriate.
The actual efficacy of interventions in the pediatric
population may be impacted by changes in
pharmacokinetics and pharmacodynamics due to
maturation and development [2, 31, 32, 34, 59, 61, 66,
72, 78–87], insufficient data of high-quality and/or
low-quantity [72, 73, 75, 76, 79], and incorrect
predictions through the extrapolation of adult data
[30, 32, 64, 65, 88–93]. Specifically, the reporting
of the rationale and evidence for the comparator
treatments used in the trial allow the reader to
make appropriate scientific interpretations of the
results [2, 30, 86, 87, 94–101]. Finally, our research
found abundant support for the reporting of the
validity of the outcomes used in every included
age group to allow the reader to assess any potential
for invalid outcome selection and measurement.
Outcomes in all trials are recommended to be
validated in the target population. Not all valid
outcomes in adults are either relevant or valid in
pediatric populations [31, 102–106] and not all
child health outcomes are valid across various
developmental stages within pediatrics [107–111].
Valid patient reported outcomes for adults may
not be valid for young children [102–104, 112],
proxy reports may differ from child experience
[102, 112–116], symptoms in children may differ from
those in adults, and what is considered healthy may
differ between adults and children [21, 61, 106, 107,
117–122]. Also, due to these changes in outcomes
measurement, validity of outcomes, and adverse
impacts of treatment on the developmental trajectory
of pediatric participants over time, the reporting
of long-term monitoring of outcomes was also
recommended [29, 34, 50, 123–131].
2. Research ethics. Another analytic theme for the
reporting of an item was to allow the reader to
assess the ethics of the trial, including whether
children were protected from unnecessary research.
Pediatric research should be limited to studies
addressing only essential scientific questions that
produce useful information [78, 118, 132]. It is not
ethical to conduct research in children if comparable
results can be obtained by using other methods,
such as valid extrapolations from adult data or from
existing data on off-label use [66, 96, 99].
Ensuring that research does not expose participants
to greater than minimal risk is an ethical requirement
of pediatric research and trials must take measures to
reduce risks for participants. This involves reducing
the pain, discomfort, distress, and invasiveness of the
procedures used [31, 32, 72, 86, 88, 132–136].
Reporting blood-sampling procedures allows the
reader to critically appraise whether the volume of
blood drawn in pediatric studies was minimized and
sampling was infrequent as possible [32, 60, 78, 86, 87,
133, 134, 137]. Additionally, inclusion of whether a
Data and Safety Monitoring Board was established
enables the audience to evaluate the presence of
quality and safety oversight before and during the
trial [22, 86, 87, 118, 138–143]. Further, detailed
reporting of the trial’s comparator treatments allows
the ethical implications and risks associated with
certain comparators to be assessed by the reader,
like the risk of exposure to novel or off-label agents
[134], the use of placebo or withholding of some
standard care [61, 87, 101, 144, 145], and the inability
of pediatric subjects to provide informed consent to
use of some comparator groups [134, 146] make
reporting of the rationale and evidence for the
comparators used in the trial a necessity.
Children may experience different harms from
treatment than adults [33, 120, 147], which may
not be realized until years after the trial [32, 61,
66, 72, 74, 78, 88, 96, 118, 125, 126, 132, 134,
135, 148–153]. The onset of potential harms after
the conclusion of the trial, possible changes in the
trial’s results due to the biological development of the
participant, potential emergence of rare events later in
the life of a child, and the increased ability of a child
to better describe the harm due to their cognitive
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maturation requires that study researchers report
long-term outcome monitoring procedures and how
long-term safety of participants will be addressed
[29, 34, 50, 123–131].
The assent of a child, when possible, is another ethical
requirement for participation in pediatric trials.
Therefore, the reporting of what research information
was provided to children and how assent was
established was recommended as age, competence,
and maturity dictates the appropriateness of the
aforementioned elements [32, 61, 72, 74, 78, 88, 96,
118, 125, 126, 132, 134, 135, 148–153]. Reporting this
information allows the reader to assess the ethics of
the trial, by evaluating whether the information and
assent process was appropriate, and whether the
autonomy of the child was respected.
3. Internal validity. Finally, the analytic theme of internal
validity was identified through our systematic
reviews. Transparent reporting of certain study
design, conduct, and analysis items allows the
reader to assess the internal validity of the trial,
including the extent to which all forms of bias
were contained. As in trials outside child health,
proper randomization, allocation concealment,
blinding of intervention and outcome measurement,
and full non- selective outcome reporting are
crucial. Specifically, confounders (such as body
mass index) [56, 108], assessment procedures
[107–111], and test cut-off ranges may change
across age and development groups. Also, the
reporting of stratified randomization considerations
allows the reader to assess whether the stratification
variables were appropriate. The reporting of effect
modification considerations allows the reader to
assess the appropriateness of the considerations
[87, 98], whether they were considered a priori
[89, 154] and the risk of bias in the trial by
evaluating whether pediatric-specific age and
development-related confounding variables were
accounted for [34, 70, 89, 117, 155, 156]. The
reporting of the subgroup analyses allows the
reader to critically assess the validity of the trial
analyses by evaluating whether analyses were decided
upon before or after the trial, and whether analyses
were appropriate [142, 157].
Discussion
Pediatric-specific trial protocols and trial reports need
pediatric-specific guidance informed by evidence to
contain bias, maximize legitimacy, and enable correct in-
terpretation, knowledge translation, and application.
Previous systematic reviews have shown inappropriate
reporting of pediatric protocols [24–26] and pediatric
trial reports [3, 4, 6, 9–17]. Despite repeated calls for
pediatric-specific reporting guidance in the literature,
there has been no previous work completed to build the
evidence base to create this guidance. The recommenda-
tions and evidence we identified and summarized in this
paper provide a basis for decisions to be made in a con-
sensus meeting for the development of pediatric exten-
sions to the current reporting guidelines. Building on
the success of the SPIRIT and CONSORT guidelines,
these evidence-based guidelines will help to ensure
that authors who are looking to appropriately report
pediatric trial protocols and trial reports have evidence-
based guidance.
Limitations and strengths
While the MEDLINE and CMR databases were selected
for their relevance and comprehensiveness, our elec-
tronic search was restricted to these two databases, and
to English publications only. Publications were eligible
based on content rather than type, and it is possible that
eligible publications of types not normally indexed in
electronic databases were missed. Although we did ex-
tract the level of evidence associated with the recom-
mendations we identified, the quality of the evidence
varied, and was not formally assessed due to the nature
of the review. Our reviews included evidence from all
publication types, most of which were narrative review
publications. There is no tool for assessing the quality of
evidence underpinning recommendations that would be
appropriate for such reviews, the majority of the publica-
tions, which could also be applied to all other included
publications [47]. As in previous qualitative systematic
reviews supporting reporting guideline development, we
included all eligible studies regardless of their quality
[47]. Quality assessment was not necessary to meet the
objectives of our systematic reviews, as they were de-
signed to gather all relevant descriptive evidence and
recommendations, and to report qualitative rather than
quantitative results in accordance to best practices for
reporting guideline development [43]. Due to the lack of
publications that focus on the reporting of pediatric tri-
als and protocols, and the difficulty of identifying a
priori which papers would contain evidence and recom-
mendations for reporting items, our study was struc-
tured to maximize sensitivity and capture all available
evidence.
Our two systematic reviews build on the SPIRIT sys-
tematic review by Tetzlaff et al. [23], but include evi-
dence from all publication types rather than from
guidelines alone, and focus on pediatrics, where a need
for guidance has been identified. This approach will help
to improve the legitimacy of guidelines built upon this
evidence, and to contain bias that would result from cre-
ating guidelines based on expert opinion alone. Our ex-
tensive search of multiple databases without time limits,
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along with our sensitive approach to gathering evidence,
maximized the applicable evidence that could be identi-
fied. The qualitative nature of the data extraction
process ensured that the context of the recommenda-
tions and evidence were contained within the reviews.
We believe this allows the results to be useable and
translatable to guideline developers, informing the ne-
cessary next step in creating pediatric reporting guide-
line extensions. Such extensions will provide guidance to
the authors of pediatric protocols, helping to alleviate
concerns of incomplete protocol reporting and will an-
swer the repeated calls for pediatric-specific trial report-
ing to address the common repeated deficiencies in
reporting of pediatric trial reports. Together, SPIRIT-C
and CONSORT-C, when adopted by authors, will ensure
that pediatric research is reported in a way that ensures
it is useful to all stakeholders, that bias is minimized,
and that the research is not wasted.
Conclusions
Our systematic reviews identified evidence and recom-
mendations for the reporting of specific items in
pediatric trial protocols and reports. These results pro-
vide useful and translatable evidence and recommenda-
tions to underpin the existing SPIRIT and CONSORT
guidelines for reporting items when used in pediatric
trials design and reporting. Also, these results provide
foundations for pediatric-specific extensions to these
reporting standards.
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